Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer

被引：0
|
作者：
Zhifei Li [1 ]
Huan Zhao [2 ]
Huihui Hu [1 ]
Haili Shang [1 ]
Yongjing Ren [1 ]
Wenhui Qiu [3 ]
Hao Su [4 ]
Huifang Lyu [5 ]
Xiaobing Chen [1 ]
机构：
[1] Department of Oncology, the Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital, Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Canc
[2] Henan University of Traditional Chinese Medicine
[3] State Key Laboratory of Esophageal Cancer Prevention&Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, School of Pharmaceutical Sciences,Zhengzhou University
[4] The First Affiliated Hospital of Xinxiang Medical University
[5] Department of Oncology, the Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer
来源：
Chinese Journal of Cancer Research | 2024年 / 36卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R735.2 [胃肿瘤];
学科分类号：
摘要：
Gastric cancer is one of the most prevalent cancers worldwide, and human epidermal growth factor receptor 2(HER2)-positive cases account for approximately 20% of the total cases. Currently, trastuzumab + chemotherapy is the recommended first-line treatment for patients with HER2-positive advanced gastric cancer, and the combination has exhibited definite efficacy in HER2-targeted therapy. However, the emergence of drug resistance during treatment considerably reduces its effectiveness; thus, it is imperative to investigate the potential mechanisms underlying resistance. In the present review article, we comprehensively introduce multiple mechanisms underlying resistance to trastuzumab in HER2-positive gastric cancer cases, aiming to provide insights for rectifying issues associated with resistance to trastuzumab and devising subsequent treatment strategies.
引用
收藏
页码：306 / 321
页数：16
相关论文
共 50 条
  • [1] Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer
    Li, Zhifei
    Zhao, Huan
    Hu, Huihui
    Shang, Haili
    Ren, Yongjing
    Qiu, Wenhui
    Su, Hao
    Lyu, Huifang
    Chen, Xiaobing
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (03)
  • [2] Trastuzumab In HER2-Positive Metastatic Gastric Cancer
    Croxtall, Jamie D.
    McKeage, Kate
    DRUGS, 2010, 70 (17) : 2259 - 2267
  • [3] Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
    Park, Ji Soo
    Youn, Jong-Chan
    Shim, Chi Young
    Hong, Geu-Ru
    Lee, Choong-Kun
    Kim, Jee Hyung
    Park, Hyung Soon
    Heo, Su Jin
    Beom, Seung Hoon
    Kim, Hyo Song
    Rha, Sun Young
    Chung, Hyun Cheol
    Kang, Seok-Min
    Jung, Minkyu
    ONCOTARGET, 2017, 8 (37) : 61837 - 61845
  • [4] Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer
    Mishima, Saori
    Shitara, Kohei
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 825 - 830
  • [5] Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
    Wang, De-Shen
    Liu, Ze-Xian
    Lu, Yun-Xin
    Bao, Hua
    Wu, Xue
    Zeng, Zhao-Lei
    Liu, Zekun
    Zhao, Qi
    He, Cai-Yun
    Lu, Jia-Huan
    Wang, Zhi-Qiang
    Qiu, Miao-Zhen
    Wang, Feng
    Wang, Feng-Hua
    Li, Yu-Hong
    Wang, Xiao-Nan
    Xie, Dan
    Jia, Wei-Hua
    Shao, Yang W.
    Xu, Rui-Hua
    GUT, 2019, 68 (07) : 1152 - 1161
  • [6] Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
    Wong, Andrea L. A.
    Lee, Soo-Chin
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2012, 2012
  • [7] Resistance mechanisms to HER2-targeting treatment in HER2-positive gastric cancer
    Kang, Kyo Hwa
    Nam, Ah-Rong
    Park, Ji Eun
    Bang, Ju-Hee
    Ling, Jin
    Jin, Mei Hua
    Kim, Tae Yong
    Han, Sae-Won
    Song, Sang-Hyun
    Im, Seock-Ah
    Kim, Tae-You
    Oh, Do-Youn
    Bang, Yung-Jue
    CANCER RESEARCH, 2015, 75
  • [8] Emerging insights into mechanisms of trastuzumab resistance in HER2-positive cancers
    Wu, Xiaoxue
    Huang, Shuting
    He, Weiling
    Song, Mei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 122
  • [9] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
    Shitara, Kohei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun-Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Yamaguchi, Kensei
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25): : 2419 - 2430
  • [10] Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
    Kotani, Daisuke
    Shitara, Kohei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
12345